BCX-1777 in Treating Patients With Refractory Cancer - Contacts and Locations

Home

BCX-1777 in Treating Patients With Refractory Cancer

This study has been completed.

Study NCT00073944. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00073944

Locations


United States, Ohio
	Cleveland Clinic Taussig Cancer Center
	Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

BioCryst Pharmaceuticals

Investigators


Study Chair:	Alex Shalaurov, MD, PhD	Inveresk Research Group, Incorporated